Sonic Holdco, Inc.

Sonic Holdco filed an S-4 registration statement for a reverse merger combining Synlogic and Caldera Therapeutics, with Caldera raising approximately $278.0 million in a concurrent financing from qualified institutional buyers and accredited investors. Post-merger, pre-closing Caldera equityholders (excluding concurrent financing investors) will own approximately 62.8% of Parent, pre-closing Synlogic equityholders approximately 2.3%, and concurrent financing investors approximately 34.9%, on a fully diluted basis. The merger agreement values Synlogic at $18.0 million (assuming net cash of $6.0 million at closing) and Caldera at $500.0 million; Synlogic's valuation is subject to dollar-for-dollar adjustment if net cash deviates from $6.0 million, with a floor of $8.0 million.

Price data unavailable.

Synlogic stockholders face extreme dilution to 2.3% in a reverse merger that effectively hands control to Caldera and concurrent financing investors.

Reverse mergers with concurrent PIPE financings are common in biotech when a private company seeks a public listing while providing capital to the combined entity; the 2.3% post-merger ownership for Synlogic stockholders reflects severe dilution typical of distressed public shells.

Synlogic stockholders face extreme dilution to 2.3% ownership; valuation adjustment mechanism can reduce ownership further if net cash falls below $6.0 million (capped at $8.0 million valuation floor). Merger conditioned on NYSE American or other exchange listing approval, which is not guaranteed.